Dr. Frank Peacock and Dr. Damon R. Kuehl join BioTalk for a focused discussion on one of emergency medicine's most persistent challenges: accurately diagnosing and predicting outcomes in mild traumatic brain injury. As Scientific Advisory Board members for BrainBox Solutions, Inc., they walk through what happens when a patient presents to the emergency department after a fall or sports injury and why current tools, including CT scans, often leave clinicians without clear answers. The conversation explores the gap between a "normal" scan and ongoing symptoms, and what missed or uncertain diagnoses can mean for patients weeks later.

Dr. Peacock outlines the HeadSMART II study and explains why combining blood biomarkers with neurocognitive testing provides a more complete assessment than biology alone. Dr. Kuehl discusses how multi-modal data, integrated through artificial intelligence, can generate an objective score to support real-time clinical decision-making and help identify patients at risk for persistent symptoms. The episode also highlights BrainBox's leadership, including CEO Donna Edmonds, a member of the BioHealth Innovation Board of Directors, and the company's role in advancing objective mTBI testing.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. W. Frank Peacock IV is Professor of Emergency Medicine at Baylor College of Medicine. Chief Medical Officer at AseptiScope, and the founder of both a contract research organization called Comprehensive Research Associates, LLC and a medical education company named Emergencies in Medicine, LLC. Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital. He has >900 peer reviewed publications and is also the co-editor of multiple medical textbooks on heart failure, acute coronary syndromes, and traumatic brain injury.

Dr. Damon R. Kuehl is the Vice Chair of Research and Academic Affairs and Professor in the Department of Emergency Medicine at Virginia Tech, School of Medicine. He completed Medical School at University of Minnesota Medical School and his Emergency Medicine Residency at Stanford University. He has also completed residencies in Preventive Medicine and a Research Fellowship in the Center for Policy and Research in Emergency Medicine, at Oregon Health and Science University. Dr. Kuehl's research primarily focuses on diagnostic and prognostic uncertainty in brain injury. He is a lead investigator for HeadSMART II and for HeadSMART Geriatrics, a NINDS funded 3 year study to develop a diagnostic tool for head trauma in older adults. He is the founder of the Carilion Brain Injury Center and also an investigator with the Virginia Tech Center for Biomechanics studying the boundary conditions associated with injuries in older adult falls.

This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University's Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district's foundation. The guests talk about the life science assets, research strengths, and translational capabilities that define the district and explain why it is positioned to support biotechnology and advanced R&D companies.

The conversation explores how the partnership between Prince William County, George Mason University, and the City of Manassas came together, outlining the distinct roles each plays in advancing a shared strategy. The episode also introduces the NISA program, detailing how it supports companies seeking a soft-landing pathway into the district, the types of organizations best suited for the program, and the facilities, talent, and collaborative resources participants can access both immediately and over time.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Jaehan Park is Founder and CEO of NAUGEN, a global innovation accelerator advancing novel technologies across life sciences and deep tech. With more than 25 years of experience in strategy and business development, he has led collaborations spanning cancer immunotherapy, vaccines, and biologics with global pharmaceutical companies and academic institutions. He leads the NISA Program in partnership with George Mason University and serves as a Mentor-in-Residence at KIC DC, supporting international startups entering U.S. markets.

Amy Adams is Executive Director of George Mason University's Institute for Biohealth Innovation, where she advances biohealth research and innovation across more than 300 faculty and thousands of students. Her work focuses on partnerships, shared research infrastructure, and building hubs that connect academia with industry. She is co-leading the development of the Innovation District anchored at Mason's SciTech campus and serves on the boards of BioHealth Innovation and the Association of University Research Parks.

Christina Winn leads the Prince William County Department of Economic Development, guiding investment, business growth, and redevelopment efforts across one of Virginia's largest counties. She is overseeing the development of a research-driven Innovation District in partnership with George Mason University and the City of Manassas, supported by a GO Virginia grant. Her career includes leading large-scale economic development initiatives that have driven significant capital investment, job creation, and national visibility for the region.

IonQ Vice President and GM of Quantum Platform Matthew Keesan joins BioTalk for a clear look at how they are advancing quantum computing from its home base in the BioHealth Capital Region. He shares the story of IonQ's Maryland roots and explains quantum computing in straightforward terms for listeners seeking a high-level understanding. The conversation moves into why biohealth leaders should track the hardware race, what distinguishes IonQ's approach, and how quantum is already being paired with AI to strengthen modeling and analysis. Keesan walks through early use cases showing traction today, challenges common myths about timelines, and shares which biohealth applications he expects to gain mainstream momentum by 2030.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Matthew Keesan is Vice President and GM of Quantum Platform at IonQ and a member of the BHI Board. He joined IonQ in 2017 to lead the development of the company's Quantum OS, the software stack that controls IonQ's quantum computers. In 2021, he oversaw the launch of IonQ's Harmony systems on Amazon Braket, Microsoft Azure Quantum, and Google Cloud, making IonQ the first quantum hardware provider available across all three hyperscalers. He built IonQ's security function to meet commercial and government frameworks, including SOC 2, NIST 800-171, NIST 800-53, and ISO 27001, and established a globally distributed operations team managing IonQ's fleet of quantum computers across the United States and Europe.

Before joining IonQ, Keesan served as CTO of the restaurant technology company Ando, which was acquired by Uber, and advised startups in manufacturing, e-commerce, and identity-as-a-service. He also helped create the technology behind the interactive HBO series Mosaic with Steven Soderbergh. He holds patents in quantum compilation, hybrid quantum computation, and quantum control automation, and has co-authored papers published in Nature and Physical Review A.

William Hurley, known widely as Whurley, joins BioTalk for a deep look at how quantum computing is moving from theory into practical use across the biohealth landscape. He opens the conversation with an introduction to Strangeworks and explains why the company is focused on making quantum computing more accessible for real-world problem-solving. The discussion explores how quantum could support breakthroughs in genomics and personalized medicine, improve the way clinical trials are modeled, and strengthen manufacturing and supply chain operations. Whurley also talks through the ingredients required for regional leadership in this space, including infrastructure, strategic partnerships, and a specialized workforce. He shares his view on what will distinguish successful players in quantum from those who overpromise or misread the market, and closes with a forward look at the convergence of quantum, AI, and biotechnology and the impact these capabilities could have on healthcare innovation. The conversation follows his recent keynote appearance at the BioHealth Capital Region Forum this past September.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Whurley is the founder and CEO of Strangeworks, an Eisenhower Fellow, a Senior Member of the IEEE, founder of the Quantum Computing Standards Workgroup at the IEEE, the first Ambassador to CERN and Society, and co-author of "Quantum Computing for Babies" and the forthcoming "Quantum Computing for Dummies." He previously served as a Managing Director at Goldman Sachs following its acquisition of his startup Honest Dollar. Before that he founded Chaotic Moon Studios, which was acquired by Accenture.

Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia's growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth's life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He also discusses Virginia's use of public-private partnerships to accelerate industry growth, strengthen the talent pipeline, and support emerging hubs across the Commonwealth. The conversation closes with a look at Virginia's role in the BioHealth Capital Region and how the regional identity helps amplify the state's message as it continues building a competitive biohealth ecosystem.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Juan Pablo Segura is the Secretary of Commerce and Trade for the Commonwealth of Virginia. He leads 13 agencies focused on economic growth, business development, and industry expansion across the state. Before entering public service, Segura spent his career building companies in the digital health sector, most notably as a founder of Babyscripts, a widely adopted maternity care platform. His work has been recognized by Startup Health, CTIA, EY, and the White House. He is a CPA and a graduate of the University of Notre Dame, and he lives in Henrico, Virginia with his family.

This episode brings together three leaders working at the intersection of pediatric innovation, health security, and early-stage commercialization. Kolaleh Eskandanian, Program Director of SPARK, is joined by founders Dori Jones of AcQumen Medical and Jugal Suthar of Vesynta for a conversation about advancing breakthrough solutions for children. They discuss the mission behind the BARDA-funded SPARK for Innovations in Pediatrics Hub at Children's National Hospital, the challenges of developing technologies for pediatric populations, and the impact of public-private partnerships in moving lifesaving tools to market. Dori and Jugal share what their companies are building, the inflection points that shaped their journeys, and how BioHealth Innovation's Entrepreneur-in-Residence program supported their progress. The group reflects on lessons learned, the value of mentorship, and how collaborative accelerator ecosystems help drive breakthroughs in pediatric care, preparedness, and health equity.

Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

Dr. Kolaleh Eskandanian is a nationally recognized leader in pediatric health innovation with more than twenty years of experience across academia, government, and industry. She previously served as Vice President and Chief Innovation Officer at Children's National Hospital, where she founded Innovation Ventures and secured significant federal funding, patents, and licensed technologies. She now leads the BARDA-funded SPARK Accelerator Hub for Pediatrics and serves as Chief Strategy and Innovation Officer at Compremium AG, while also supporting early-stage innovators as an angel investor with Citrine Angels.

Dori Jones is the Co-Founder and CEO of AcQumen Medical, a medtech company developing UltraTrac, the first ultrasound-guided impedance technology designed for rapid assessment of hemodynamics in critically ill infants and children. She brings nearly two decades of experience across R&D, clinical education, and commercialization roles supporting cardiac and critical care devices at organizations ranging from early startups to Abbott and Medtronic. Her commitment to pediatric innovation is shaped in part by her experience as the mother of a NICU and PICU patient.

Dr. Jugal Suthar is the Co-Founder and CEO of Vesynta, a precision medicine company developing the DosoLogic platform, the first marketplace-enabled precision prescribing software aimed at improving accuracy and safety for every patient. His background includes clinical work as a hospital pharmacist and roles in drug development in the pharmaceutical industry. His PhD in precision medicine fuels his focus on bringing personalized dosing insights to populations often underrepresented in clinical research.

In this episode of BioTalk, CEO Gerard Eldering explains how Perfusion Medical is addressing a problem that trauma physicians and military medics have been struggling with for decades: capillary compression. Perfusion Medical is developing a drug aimed at treating hemorrhagic shock and other ischemic conditions. PM‑208 is a novel IV therapeutic designed to restore capillary blood flow, resolve ischemia, and protect vital organs. The team has advanced this work with $19 million in Department of Defense funding. He describes the scale of the unmet need, why PM‑208 is both organ- and disease‑agnostic, and how its simple formulation and strong safety profile position it for broad medical use.

Eldering also reflects on the company's path through the BioHealth Capital Region Crab Trap Competition. After a second‑place finish a few years earlier, Perfusion Medical returned to the stage and won the 2025 competition. He shares what that experience has meant for the team and why building the company in the BioHealth Capital Region—particularly from a Virginia base—has been a strategic advantage.

The conversation moves through the role of early federal funding and programs like SBIR/STTR in de‑risking breakthrough therapies, and how university research partnerships have strengthened PM‑208's development. Eldering highlights how public‑private collaboration has shaped the company's progress and made it possible to push a complex medical solution toward patients more quickly.

Editing and post-production work for this episode was provided by The Podcast Consultant - https://thepodcastconsultant.com/0

About Gerard Eldering Gerard Eldering is the CEO of Perfusion Medical and a nationally recognized expert in technology transfer and venture formation. Since becoming an entrepreneur in 2007, he has helped launch more than a dozen startups, raised more than $15 million in seed funding, and led the turnaround and sale of a technology consulting firm. Before founding Perfusion Medical, he built and led The MITRE Corporation's Technology Transfer Office. Eldering is a U.S. Air Force veteran who served as a helicopter pilot and instructor. He holds a B.A. in Physics, an M.B.A., and is a registered patent agent.

In this episode of BioTalk, Rich Bendis sits down with Councilman Brian Knudsen, Jamie Schwartz of UNLV, and Vance Farrow from the Nevada Governor's Office of Economic Development to spotlight the rapid emergence of Southern Nevada as a rising force in the biohealth landscape. The conversation covers the launch of the $10 million BioHealth Innovation Challenge, the Desert Forge Venture Fund, and the revitalization of BioTech Vegas, all designed to attract industry anchors, fuel early-stage startups, and cultivate a thriving innovation ecosystem. They also explore how strong collaboration between local and state government, academic institutions, and entrepreneurs is propelling Las Vegas into a new era of health innovation, with a focus on brain health, sports science, and workforce development.

Editing and post-production work for this episode was provided by The Podcast Consultant: thepodcastconsultant.com

Councilman Brian Knudsen was elected to represent Ward 1 in 2019 and re-elected in 2024, continuing his long-standing commitment to public service and community-building in Las Vegas. On December 21, 2022, he was named Mayor Pro Tem. Brian has been instrumental in driving the transformation of the Las Vegas Medical District and expanding public health infrastructure throughout the city. He serves on several boards, including the Southern Nevada Health District and the Regional Transportation Commission, and is a vocal advocate for policies that strengthen healthcare, public safety, and inclusive economic development.

Jamie Schwartz, MBA, is Director of Industry Engagement at the University of Nevada, Las Vegas (UNLV) Office of Economic Development and President of the Board for BioTech Vegas. With deep experience in public-private partnerships and academic-industry collaboration, she works at the intersection of research, innovation, and commercialization to strengthen Southern Nevada's biotech and health innovation landscape.

Vance Farrow serves as the Healthcare Industry Specialist for the Nevada Governor's Office of Economic Development. His work focuses on attracting and expanding healthcare businesses throughout the state, aligning talent development efforts, and building the infrastructure needed to support a robust biohealth sector. He plays a critical role in shaping state policy and investment strategies for the industry.

In this episode of BioTalk with Rich Bendis, Harry Coker, Jr., Secretary of the Maryland Department of Commerce, joins the podcast to discuss Maryland's rising momentum as a global biohealth and technology leader. Secretary Coker shares his unique journey from the CIA, NSA, and White House to leading Maryland's economic development strategy, highlighting the state's strengths in life sciences, its appeal to global investors, and the importance of public-private partnerships in accelerating innovation.

Topics include Maryland's recent recognition as a Top 3 biopharma hub, the decision to prioritize Life Sciences and Computational Biology as "Lifehouse" sectors, and how the state is leveraging the BioHealth Capital Region identity to unite and expand its regional leadership. He also outlines Maryland's case for investment and why collaboration will be central to "Winning the Decade."

Editing and post-production work for this episode was provided by The Podcast Consultant.

The Honorable Harry Coker, Jr. was appointed by Governor Wes Moore as Maryland's Secretary of Commerce in 2025. He is a retired senior executive from the CIA and NSA, former National Cyber Director at the White House, and a career Naval Officer. Coker's leadership is shaped by decades of public service at the highest levels of national security and technology. At the Maryland Department of Commerce, he leads efforts to build an equitable, competitive economy centered around innovation, inclusion, and impact.

Building Maryland's BioHealth Future: Maryland Commerce's Stefanie Trop on Growing the Life Sciences Sector

In this episode of BioTalk with Rich Bendis, Stefanie Trop, Ph.D., Director of Life Sciences at the Maryland Department of Commerce joins the conversation to discuss Maryland's position as a leading life sciences hub. Stefanie shares how the Department of Commerce supports company attraction and growth through programs like Global Gateway, and how it's amplifying the state's recent #3 biopharma hub ranking. The discussion also explores Maryland's unique ecosystem, including the work of the Governor's Life Sciences Advisory Board, the state's leadership in computational health, and the importance of industry collaboration during BioHealth Capital Region Week.

Editing and post-production work for this episode was provided by The Podcast Consultant. Dr. Stefanie Trop brings a unique blend of hands-on scientific expertise and high-level strategic insight. With a Ph.D. in Molecular Microbiology and Immunology, she has worked at the ground level in immunology, clinical trials, and vaccine development, while also driving growth through scientific partnerships and business development. Her deep understanding of the science and passion for problem solving guides her ability to build effective collaborations that advance both innovation and commercial success.

At the Maryland Department of Commerce, Stefanie works to connect Maryland's life sciences companies with national and global resources, expanding the industry's impact at home and globally. In current and prior roles, she bridges communication gaps between scientific and business teams, ensuring that customer needs translate into innovative products and business wins.

In this episode of BioTalk, Rich Bendis welcomes Dr. Stacey Adam, Vice President of Science Partnerships, Translational Science at the Foundation for the National Institutes of Health (FNIH), to discuss how public-private partnerships are advancing scientific innovation. Dr. Adam introduces the mission of FNIH and its unique role in bridging government, industry, and academia to accelerate biomedical progress. She highlights the Validation and Qualification Network (VQN), a new initiative working to overcome barriers to the adoption of New Approach Methodologies (NAMs) and explains how cross-sector collaboration is driving its early success. The conversation explores the long-term vision of the VQN, the global perspectives shaping its approach, and how it fits into the broader NIH Complement-ARIE initiative. Dr. Adam also reflects on the significance of being headquartered in the BioHealth Capital Region and how it supports the Foundation's mission.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Guest Bio

Dr. Stacey Adam is Vice President of Science Partnerships at the Foundation for the NIH (FNIH), where she leads major public-private partnerships including the RECOVER-Treating Long COVID initiative, multiple Biomarkers Consortium projects, the Accelerating Medicines Partnerships (AMPs), and the Lung-MAP clinical trial. She also leads efforts to design new public-private partnerships focused on pediatric medical devices, cancer systems biology, and the advancement of New Approach Methodologies (NAMs) through the Validation and Qualification Network. Previously, Dr. Adam worked at Deloitte Consulting and completed a postdoctoral fellowship at Stanford University School of Medicine. She holds a PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.